Last updated: 05/02/2026 09:10:13
Study to assess demographic, pharmacologic, biomarker, clinical features and quality of life (QoL) of participants with Lupus Nephritis
EudraCT ID
Not applicable
EU CT Number
Not applicable
Trial status
Finalized
Finalized
Trial overview
Official title: LUNELORD: A descriptive, prospective study to assess demographic, pharmacologic, biomarker, clinical features and QoL of patients with LUpus NEphritis and Long-term ORgan Damage
Trial description: This is a multicenter prospective study to assess clinical characteristics, demographics, treatment and health-related quality of life (HRQoL) of lupus nephritis (LN) participants across 5 Gulf countries (United Arab Emirates [UAE], Qatar, Bahrain, Kuwait and Oman).
Primary purpose:
Not applicable
Trial design:
Not applicable
Masking:
Not applicable
Allocation:
Not applicable
Primary outcomes:
Number of participants categorized by demographic characteristics
Timeframe: At Baseline (Day 1)
Number of participants with active clinical manifestations of Lupus Nephritis
Timeframe: Up to 12 months
Number of participants with comorbidities
Timeframe: Up to 12 months
Number of participants with Severe Lupus Nephritis
Timeframe: Up to 12 months
Number of participants categorized by treatments for lupus nephritis
Timeframe: At Baseline (Day 1)
Short form health survey (SF-36) health-related quality of life domain score
Timeframe: At Baseline (Day 1)
Secondary outcomes:
Number of participants with refractory Lupus Nephritis
Timeframe: Up to 12 months
Number of participants with abnormal findings for serological markers
Timeframe: At 3, 6, 9 and 12 months
Number of participants with renal remission that were associated with clinical factors, biomarkers, and treatments
Timeframe: Up to 12 months
Percent Change from Baseline in SF-36 scores for each health domain:physical functioning, pain, role limitations due to physical health, role limitations due to emotional problem, emotional well-being, social functioning, energy/Fatigue and general health
Timeframe: Baseline (Day 1) and at 12 months
Number of participants with hospitalizations and intensive care unit (ICU) hospitalizations
Timeframe: Up to 12 months
Direct medical costs associated with lupus nephritis management
Timeframe: Up to 12 months
Number of participants with treatment for lupus nephritis by sector (public or private sector)
Timeframe: Up to 12 months
Interventions:
Other: Participant completed survey
Other: Medical chart review
Enrollment:
193
Observational study model:
Cohort
Primary completion date:
2024-31-10
Time perspective:
Prospective
Clinical publications:
Jamal Al-Saleh, Faisal Elbadawi, Rajaie Namas, Mohamed Elarabi, Samar Al-Emadi, Miral H Gharib, Khalid A Alnaqbi, Hiba Khogali, Humaid A Al Wahshi, Sadiq Abdul Baqi, Amjad Alkadi, Suad Hannawi, Samah Allam, Reem Al-Jayyousi, Mohamed Hamouda, Averyan Vasylyev, Evelina Zimovetz, Munther Khamashta. LUNELORD: A descriptive, prospective study on the demographics, disease characteristics and health-related quality of life of patients with LUpus NEphritis and long-term ORgan damage in rheumatology clinics in the Arabian Gulf. Lupus. 2026;: 9612033261432164. doi:10.1177/09612033261432164 http://dx.doi.org/10.1177/09612033261432164
PMID: 41866958
DOI: 10.1177/09612033261432164
Medical condition
Systemic Lupus Erythematosus
Product
rituximab
Collaborators
Not applicable
Study date(s)
September 2021 to October 2024
Type
Observational
Phase
Not applicable
Participation criteria
Sex
Female & Male
Age
18+ years
Accepts healthy volunteers
No
- More than or equal to 18 years of age
- Clinician diagnosed LN participants.
- Incomplete medical records to be able to assess the disease severity or absence of any of the following renal laboratory results from the medical record within the last twelve months: a. Urinary protein to creatinine ratio (UPCR) or 24-hour proteinuria or urine sediment (activity). b. Serum creatinine or estimated glomerular filtration rate (eGFR); or measured glomerular filtration rate (GFR), if eGFR is not available.
- Current or medical history of: a. Congenital or acquired immunodeficiency. b. Malignancy in active treatment phase. c. Acute viral infection, such as human immunodeficiency virus (HIV) infection, requiring hospitalization.
Inclusion and exclusion criteria
Inclusion criteria:
- More than or equal to 18 years of age
- Clinician diagnosed LN participants.
- At least one visit to the investigational center during 12 months prior to the baseline visit, recorded in medical documentation.
- Literacy in English or Arabic allowing to fully comprehend the written informed consent and study-specific patient reported questionnaires.
Exclusion criteria:
- Incomplete medical records to be able to assess the disease severity or absence of any of the following renal laboratory results from the medical record within the last twelve months: a. Urinary protein to creatinine ratio (UPCR) or 24-hour proteinuria or urine sediment (activity). b. Serum creatinine or estimated glomerular filtration rate (eGFR); or measured glomerular filtration rate (GFR), if eGFR is not available.
- Current or medical history of: a. Congenital or acquired immunodeficiency. b. Malignancy in active treatment phase. c. Acute viral infection, such as human immunodeficiency virus (HIV) infection, requiring hospitalization.
Trial location(s)
Study documents
Study report synopsis
Available language(s): English
Protocol
Available language(s): English
Statistical analysis plan
Available language(s): English
If you wish to request for full study report, please contact - [email protected]
Results overview
Refer to study documents
Recruitment status
Finalized
Actual primary completion date
2024-31-10
Actual study completion date
2024-31-10
Plain language summaries
Not applicable. GSK’s transparency policy provides for Plain Language Summaries for Interventional studies.
Additional information about the trial
Not applicable
Participate in clinical trial
Access to clinical trial data by researchers
Visit website